Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension

The TOMORROW trial of nintedanib comprised a randomised, placebo-controlled, 52-week period followed by a further blinded treatment period and an open-label extension. We assessed outcomes across these periods in patients randomised to nintedanib 150 mg twice daily or placebo at the start of TOMORRO...

Descripción completa

Detalles Bibliográficos
Autores principales: Richeldi, Luca, Kreuter, Michael, Selman, Moisés, Crestani, Bruno, Kirsten, Anne-Marie, Wuyts, Wim A, Xu, Zuojun, Bernois, Katell, Stowasser, Susanne, Quaresma, Manuel, Costabel, Ulrich
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5969333/
https://www.ncbi.nlm.nih.gov/pubmed/28993537
http://dx.doi.org/10.1136/thoraxjnl-2016-209701

Ejemplares similares

Ejemplares similares